UOC TRANSLATIONAL ONCOLOGY RESEARCH
Head: Giovanni Blandino, MD, PhD
STAFF
- Maria Giulia Rizzo, PhD
- Patrizio Giacomini, MD
- Oreste Segatto, MD
- Silvia Di Agostino
- Sara Donzelli
- Sergio Anastasi
- Valeria Canu, PhD
- Fabio Valenti, PhD
- Claudio Pulito, PhD
- Pasquale Zizza, PhD
- Angela Rizzo, PhD
- Sara Iachettini, PhD
- Eleonora Petti, PhD
- Roberto Dinami, PhD
- Luca Pompili, PhD
- Matteo Allegretti, PhD
- Elisa Tremante, PhD
- Dante Lamberti, PhD
- Giulia Regazzo, PhD
- Federica Ganci
- Marco Varmi
- Carmen D'Angelo
- Carmen Maresca
- Elena Giordani
- Rocco Fraioli
- Roberto Bernardi
- Eleva Korita
- Anna Maria Biroccio
- Chiara Turco
- Giulia Cristinziano
- Ana Belen Diaz Mendez
- Angela Dello Stritto
- Federica Rinaldi
- Elham Rahimzadeh
- Alina Palcau
- Claudia Catulli
- Giulia Orlandi
- Maria Simitakos
The research objectives of the Translational Oncology Research Unit are pursed through the integrated experimental work of the following groups:
PI Blandino
- Sara Donzelli
- Federica Ganci
- Claudio Pulito
- Federica LoSardo
- Roberto Bernardi
- Alina Palcau
- Anna Benedetti
- Francesca Romana Auciello
- Beatrice Messina
- Valeria Canu
- Silvia Di Agostino
- Vaccarella Sebastiano
- Renata Brandi
- Martina Dragonetti
- Marco Varmi
- Chiara Turco
- Gabriella Esposito
- Valentina Piastra
Blandino’s group is actively pursuing the identification of molecular biomarkers non-coding RNAs whose association with the TP53 status may predict recurrence of head and neck cancers.
PI Biroccio
- Carmen D’Angelo
- Roberto Dinami
- Sara Iachettini
- Carmen Maresca
- Angela Rizzo
- Pasquale Zizza
- Eleonora Petti
- Luca Pompili
- Manuela Porru
- Alice Carachino
- Serena De Vito
- Carlo Leonetti
Biroccio’s group is actively investigating the extra-telomeric role of TRF2 in oncogenesis with the aim to identify novel therapeutic targets for antitumoral therapies in colon cancer.
PI Giacomini
- Fabio Valenti
- Matteo Allegretti
- Elena Ricciardi
- Elena Giordani
- Sarà De Niccolò
- Rocco Fraioli
- Giovanna Ziccheddu
Giacomini’s group is actively developing and optimizing nanoparticles for cancer therapeutics, and assays to detect circulating tumor DNA ctDNA in real-life Liquid Biopsy LBstudies.
PI Rizzo
- Giulia Regazzo
- Elisa Tremante
- Ana Belen Dia Mendez
- Marta Di Giuliani
- Giulia Vari
Rizzo’s group is actively investigating the role of extracellular circulating miRNAs in hematopoietic malignancies and brain tumors as promising biomarkers for disease classification and outcome prediction.
PI Segatto
- Sergio Anastasi
- Dante Lamberti
- Giulia Cristinziano
The Segatto’s group has generated genetically defined mouse models of intrahepatic cholangiocarcinoma iCCA driven by FGFR2 fusion proteins FFP.These models are being used to identify iCCA vulnerabilities associated to oncogenic dependence from FFPs.